Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Non-Randomized, Multi-Center Pilot Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for GVHD Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

NCT07249346 is registered in ClinicalTrials.gov with Hannah Choe, MD as lead sponsor.

NCT NCT07249346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07249346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Non-Randomized, Multi-Center Pilot Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for GVHD Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Lead sponsor
Hannah Choe, MD
Phase
Phase 2
Overall status
Recruiting
Start date
January 14, 2026
Completion date
June 1, 2027
Enrollment
124 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelomonocytic leukemia, leukemia, myelodysplasia